We’re a leading healthcare company in China.
Our interests span earlier-stage, differentiated assets through late-stage and marketed products and opportunities in digital health.
Sanofi in Suzhou
At the Sanofi Institute for Biomedical Research in Suzhou, the hub of China’s R&D ecosystem, we’re elevating our early research capabilities in oncology and immuno-inflammation.
We’re one of the first pharma companies to launch our own virtual healthcare service, Amulet Health Technology, which leverages our global network to provide integrated care for chronic disease patients worldwide, with a particular focus on Asia.
Partnering Success Stories
Sanofi extended another 10 years of strategic collaboration with China Resources for Essentiale®’s distribution & promotion. The partnership helps to access more consumers with high-quality products and services from both parties and build the leading consumer health brand.
Sanofi and Innovent Biologics have entered a strategic collaboration to bring innovative medicines to patients in China by leveraging the synergy between Sanofi and Innovent’s pipeline and R&D resources with the mutual aim to address major unmet medical needs for cancer patients.
A multi-year, multi-target strategic research collaboration between Insilico Medicine and Sanofi. The collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets.
Our Partnering Lead in China
For more information, contact our Business development team
Greater China Strategy & Business Development Head